Search results for "vascular endothelial growth factor"

showing 10 items of 320 documents

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women und…

2007

Background Ovarian hyperstimulation syndrome (OHSS) is a result of ovarian overexpression of vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR2). VEGF/VEGFR2 binding disrupts cellular junctions and increases vascular permeability (VP), a characteristic of OHSS, but enhances angiogenesis, which is a fundamental step in implantation. In animals, the dopamine agonist Cabergoline (Cb2) prevents VP without affecting angiogenesis. In humans, Cb2 averts OHSS, but a possible detrimental effect on angiogenesis and implantation has not been explored. A pilot study was designed to analyze whether or not Cb2 administration, as a procedure for preventing OHSS, affects the outcome of as…

Adultmedicine.medical_specialtyCabergolinePregnancy RateReproductive Techniques AssistedOvarian hyperstimulation syndromePilot ProjectsBiologyDopamine agonistAndrologyOvarian Hyperstimulation Syndromechemistry.chemical_compoundPregnancyCabergolineInternal medicinemedicineHumansEmbryo ImplantationErgolinesOvarian follicleRetrospective StudiesPregnancyRehabilitationObstetrics and Gynecologymedicine.diseaseVascular endothelial growth factorPregnancy ratemedicine.anatomical_structureEndocrinologyReproductive MedicinechemistryDopamine AgonistsGestationFemalemedicine.drugHuman Reproduction
researchProduct

Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF r…

2006

No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertile women treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion of vascular endothelial growth factor (VEGF)activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist(SU5416).However,duetoitstoxicity(thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, use…

AgonistVascular Endothelial Growth Factor Amedicine.medical_specialtyCabergolinemedicine.drug_classAngiogenesisOvarian hyperstimulation syndromeNeovascularization PhysiologicBiologyDopamine agonistCapillary Permeabilitychemistry.chemical_compoundOvarian Hyperstimulation SyndromeEndocrinologyCorpus LuteumInternal medicineCabergolinemedicineAnimalsRNA MessengerErgolinesPhosphorylationRats WistarReceptors Dopamine D2Kinase insert domain receptorReceptor antagonistmedicine.diseaseVascular Endothelial Growth Factor Receptor-2RatsVascular endothelial growth factorDisease Models AnimalEndocrinologychemistryDopamine AgonistsFemalemedicine.drugEndocrinology
researchProduct

Novel 3-Azaindolyl-4-arylmaleimides Exhibiting Potent Antiangiogenic Efficacy, Protein Kinase Inhibition, and Antiproliferative Activity

2012

Tumor growth and metastasis are highly associated with the overexpression of protein kinases (PKs) regulating cell growth, apoptosis resistance, and prolonged cell survival. This study describes novel azaindolyl-maleimides with significant inhibition of PKs, such as VEGFR, FLT-3, and GSK-3β which are related to carcinogenesis. Furthermore, these compounds exhibit high kinase selectivity and potent inhibition of angiogenesis and cell proliferation, offering versatile options in cancer treatment strategies.

AngiogenesisAngiogenesis InhibitorsApoptosisChick EmbryoPharmacologymedicine.disease_causeMetastasisMaleimidesNeovascularizationGlycogen Synthase Kinase 3Structure-Activity RelationshipNeoplasmsDrug DiscoveryHuman Umbilical Vein Endothelial Cellspolycyclic compoundsmedicineAnimalsHumansProtein kinase AProtein Kinase InhibitorsGSK3BCells CulturedCell ProliferationGlycogen Synthase Kinase 3 betaMolecular StructureNeovascularization PathologicKinaseChemistryCell growthCell CycleVascular Endothelial Growth Factor Receptor-3medicine.diseaseVascular Endothelial Growth Factor Receptor-2Growth Inhibitorsfms-Like Tyrosine Kinase 3Molecular Medicinemedicine.symptomCarcinogenesisJournal of Medicinal Chemistry
researchProduct

Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

2011

Cancer remains one of the major causes of death worldwide. The switch to pathological angiogenesis is a key process in the promotion of cancer and consequently provides several new and promising targets to anticancer therapy. Thus, antagonizing angiogenesis cuts off the tumor's oxygen and nutrition supply. This review focuses on angiogenesis inhibitors as option for cancer treatment. Modes of action, adverse effects, mechanisms of resistance as well as new developments are highlighted. One approach in angiogenesis inhibition is intermitting the further VEGF (vascular endothelial growth factor) signal pathway with monoclonal antibodies. Bevacizumab is a highly specific recombinant humanized …

Angiogenesismedicine.drug_classGenisteinAngiogenesis InhibitorsAntineoplastic AgentsBiologyPharmacologyMonoclonal antibodyBiochemistryReceptor tyrosine kinaseNeovascularizationSmall Molecule Librarieschemistry.chemical_compoundGrowth factor receptorNeoplasmsDrug DiscoverymedicineAnimalsHumansPharmacologyBiological ProductsNeovascularization PathologicVascular Endothelial Growth FactorsOrganic ChemistryCancerAntibodies Monoclonalmedicine.diseaseAntineoplastic Agents PhytogenicVascular endothelial growth factorchemistrybiology.proteinMolecular Medicinemedicine.symptomCurrent medicinal chemistry
researchProduct

Priming with proangiogenic growth factors and endothelial progenitor cells improves revascularization in linear diabetic wounds

2014

In the present study, we investigated whether proangiogenic growth factors and endothelial progenitor cells (EPCs) induce favourable effects on cutaneous incisional wound healing in diabetic mice. The proangiogenic effects of human EPCs were initially analyzed using a HUVEC in vitro angiogenesis assay and an in vivo Matrigel assay in nude mice (n=12). For the diabetic wound model, 48 Balb/c mice with streptozotocin (STZ)-induced diabetes were divided randomly into 4 groups (12 mice in each group). Subsequently, 3, 5 and 7 days before a 15-mm full-thickness incisional skin wound was set, group 1 was pre-treated subcutaneously with a mixture of vascular endothelial growth factor (VEGF)/basic …

Angiogenesismedicine.medical_treatmentBasic fibroblast growth factorMice NudeNeovascularization Physiologicwound healingdiabetic miceDiabetes Mellitus ExperimentalAndrologychemistry.chemical_compoundMiceTensile StrengthGeneticsHuman Umbilical Vein Endothelial CellsMedicineAnimalsHumansProgenitor cellprimingendothelial progenitor cellsMatrigelMice Inbred BALB Cbiologybusiness.industryGrowth factorStem CellsEndothelial CellsGeneral MedicineArticlesVascular endothelial growth factorproangiogenicDrug CombinationschemistryImmunologyMicrovesselsbiology.proteincardiovascular systemIntercellular Signaling Peptides and ProteinsBiological AssayProteoglycansCollagenLamininbusinessWound healingPlatelet-derived growth factor receptorStem Cell TransplantationInternational Journal of Molecular Medicine
researchProduct

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

2007

Angiogenesis is the process by which new blood vessels are created from pre-existing vessels. It is essential for the growth and development of normal cells and tissues during embryonic and neonatal development and of tumour cells. Solid tumours rely on having an extensive network of blood vessels for growth and survival. The key mediator of angiogenesis, vascular endothelial growth factor-A (VEGF-A), is critical for the growth of tumours and their subsequent metastasis and is known to initiate angiogenesis. Bevacizumab is a humanized immunoglobulin G monoclonal antibody that binds to VEGF with high specificity, thereby blocking VEGF-mediated signalling pathways and thus angiogenesis. Clini…

Antimetabolites AntineoplasticBevacizumabColorectal cancerAngiogenesisNeovascularization PhysiologicAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMetastasisNeovascularizationchemistry.chemical_compoundHumansMedicineDrug InteractionsPharmacology (medical)Neoplasm MetastasisSurvival ratePharmacologybusiness.industryAntibodies Monoclonalmedicine.diseaseBevacizumabSurvival RateVascular endothelial growth factorchemistryImmunologyMonoclonalCancer researchDrug Therapy CombinationFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct

Arterial hypertension in cancer: The elephant in the room

2019

The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, var…

Arterial hypertensionVascular Endothelial Growth Factor AAnthracyclines Anti VEGF agents Anti-hypertensive therapy Arterial hypertension Cancer Cardiotoxicitymedicine.medical_specialtyAnti VEGF agentmedicine.medical_treatmentAntineoplastic AgentsBlood PressureAnthracycline030204 cardiovascular system & hematologyAnthracyclines; Anti VEGF agents; Anti-hypertensive therapy; Arterial hypertension; Cancer; Cardiotoxicity; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Humans; Hypertension; Neoplasms; Vascular Endothelial Growth Factor A03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansAnthracyclines030212 general & internal medicineAnti-hypertensive therapyAdverse effectIntensive care medicineAntihypertensive AgentsCancerChemotherapyCardiotoxicitybusiness.industryAnti VEGF agentsCancermedicine.diseaseComorbidityCardiotoxicityDiscontinuationBlood pressureHeart failureHypertensionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Asphyxia Activates P65 and Induces VEGF-A Gene Expression in Retina and Choroid from Newborn Piglets

2011

Objective: Exposure to lower oxygen causes oxidative stress and promotes angiogenesis. Asphyctic neonates have shown higher cord-blood vascular endothelial growth factor (VEGF). We hypothesized that retina and choroid having a different circulatory regulation (choroid lacks vascular auto-regulation) would acutely stimulate angiogenesis in response to short and severe hypoxemia.

AsphyxiaPathologymedicine.medical_specialtyRetinaFetusbusiness.industryAngiogenesismedicine.disease_causeeye diseasesVascular endothelial growth factorchemistry.chemical_compoundmedicine.anatomical_structureEndocrinologychemistryInternal medicinePediatrics Perinatology and Child HealthCirculatory systemmedicinesense organsChoroidmedicine.symptombusinessOxidative stressPediatric Research
researchProduct

Effects of acute exercise, exercise training, and diabetes on the expression of lymphangiogenic growth factors and lymphatic vessels in skeletal musc…

2007

Blood and lymphatic vessels together form the circulatory system, allowing the passage of fluids and molecules within the body. Recently we showed that lymphatic capillaries are also found in the capillary bed of skeletal muscle. Exercise is known to induce angiogenesis in skeletal muscle, but it is not known whether exercise has effects on lymphangiogenesis or lymphangiogenic growth factors. We studied lymphatic vessel density and expression of the main lymphangiogenic growth factors VEGF-C and VEGF-D and their receptor VEGFR-3 in response to acute running exercise and endurance exercise training in the skeletal muscle of healthy and diabetic mice. VEGF-C mRNA expression increased after t…

Blood GlucoseMalemedicine.medical_specialtyTime FactorsPhysiologyPhysical ExertionVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DPhysical exercisePolymerase Chain ReactionDiabetes Mellitus ExperimentalMiceEndurance trainingPhysiology (medical)Internal medicinemedicineLymphatic vesselAnimalsRNA MessengerLymphangiogenesisMuscle SkeletalLymphatic Vesselsbusiness.industryBody WeightSkeletal muscleVascular Endothelial Growth Factor Receptor-3ImmunohistochemistryLymphangiogenesisLymphatic systemEndocrinologymedicine.anatomical_structureVascular endothelial growth factor CGene Expression RegulationCirculatory systemCardiology and Cardiovascular MedicinebusinessAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Modulation of platelet activation and initial cytokine release by alloplastic bone substitute materials.

2010

Objectives: Platelet-derived cytokines play a crucial role in tissue regeneration. In regenerative dental medicine, bone substitute materials (BSM) are widely used. However, initial interactions of BSM and platelets are still unknown. The aim of this study was to evaluate the potential of platelet activation and subsequent initial cytokine release by different commercial alloplastic BSM. Material and methods: Eight commercial BSM of different origins and chemical compositions (tricalcium phosphate, hydroxyapatite, bioactive glass: SiO2 and mixtures) were incubated with a platelet concentrate (platelet-rich plasma, PRP) of three healthy volunteers at room temperature for 15 min. Platelet cou…

Blood PlateletsCalcium PhosphatesVascular Endothelial Growth Factor APlatelet Aggregationmedicine.medical_treatmentPharmacologyCell Degranulationlaw.inventionlawmedicineHumansPlateletPlatelet activationPlatelet-Derived Growth FactorbiologyChemistryPlatelet CountPlatelet-Rich PlasmaGrowth factorDegranulationFlow CytometryPlatelet ActivationSilicon DioxideP-SelectinCytokineDurapatiteBioactive glassPlatelet-rich plasmaImmunologyBone Substitutesbiology.proteinOral SurgeryPlatelet-derived growth factor receptorClinical oral implants research
researchProduct